Injections, Intravenous

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with early stage Alzheimer’s disease.

Use of a second anti-tumor necrosis factor agent resulted in early clinical response in nearly 50% of patients with ulcerative colitis and long-term remission in about 30%, with no difference reported between IV and subcutaneous agents.